5.3.3 Viral hepatitis

Drugs used, not listed here:

5.3.3.1 Chronic hepatitis B

Entecavir
  • Tablets 500 micrograms, 1mg
  • Oral solution 50 micrograms

Notes

  1. NICE TA153: Entecavir is recommended as an option for the treatment of people with chronic HBeAg-positive or HBeAg-negative hepatitis B in whom antiviral treatment is indicated (August 2008)
Telbivudine
  • NICE TA154: Telbivudine (Sebivo) is not recommended for the treatment of chronic hepatitis B (August 2008)

5.3.3.2 Acute and Chronic hepatitis C

NHS England (NSHE) will routinely commission antivirals for adults with acute hepatitis C (HCV), including the treatment of acute HCV infection in immunosuppressed adults (e.g. post transplantation patients) (see NHSE Commissioning Policy for more details).

MHRA Drug Safety Update (October 2018): Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels. Monitor thyroid-stimulating hormone (TSH) in patients treated with levothyroxine for at least the first month after the start and end of ritonavir treatment

MHRA Drug Safety Update (December 2018): Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes

Exviera®

(Dasabuvir)

  • Tablets 250mg

Notes

  1. NICE TA365: Ombitasvir-paritaprevir-ritonavir (Viekirax) with or without dasabuvir (Exviera) is recommended as an option for treating genotype 1 or 4 chronic hepatitis C in adults (November 2015) (For NHS England commissioned treatment of acute hepatitis C, see above)
Zepatier®

(Elbasvir-grazoprevir)

  • Tablets 50mg/ 100mg

Notes

  1. NICE TA413: Elbasvir-grazoprevir (Zapatier) is recommended as an option for treating genotype 1 or 4 chronic hepatitis C in adults (October 2016) (For NHS England commissioned treatment of acute hepatitis C, see above)
Maviret®

(Glecaprevir-pibrentasvir)

  • Tablets modified-release 100mg/ 40mg

Notes

  1. NICE TA499: Glecaprevir–pibrentasvir (Maviret) is recommended as an option for treating chronic hepatitis C in adults (January 2018) (For NHS England commissioned treatment of acute hepatitis C, see above)
Harvoni®

(Ledipasvir-sofosbuvir)

  • Tablets 90mg/ 400mg

Notes

  1. NICE TA363: Ledipasvir-sofosbuvir (Harvoni) is recommended as an option for treating chronic hepatitis C in adults (November 2015) (For NHS England commissioned treatment of acute hepatitis C, see above)
Sovaldi®

(Sofosbuvir)

  • Tablets 400mg

Notes

  1. NICE TA330: Sofosbuvir (Solvaldi) is recommended for treating chronic hepatitis C in adults (February 2015) (For NHS England commissioned treatment of acute hepatitis C, see above)
Epclusa®

(Sofosbuvir-velpatasvir)

  • Tablets 400mg/ 100mg

Notes

  1. NICE TA430: Sofosbuvir–velpatasvir (Epclusa) is recommended as an option for treating chronic hepatitis C in adults (January 2017) (For NHS England commissioned treatment of acute hepatitis C, see above)
Vosevi®

(Sofosbuvir-velpatasvir-voxilaprevir)

  • Tablets 400mg/ 100mg/ 100mg

Notes

  1. NICE TA507: Sofosbuvir-velpatasvir-voxilaprevir (Vosevi) is recommended as an option for treating chronic hepatitis C in adults (February 2018) (For NHS England commissioned treatment of acute hepatitis C, see above)
Viekirax®

(Ombitasvir-paritaprevir-ritonavir)

  • Tablets 12.5mg/ 75mg/ 50mg

Notes

  1. NICE TA365: Ombitasvir-paritaprevir-ritonavir (Viekirax) with or without dasabuvir (Exviera) is recommended as an option for treating genotype 1 or 4 chronic hepatitis C in adults (November 2015) (For NHS England commissioned treatment of acute hepatitis C, see above)

 

Home > Formulary > Chapters > 5. Infections > 5.3 Antiviral drugs > 5.3.3 Viral hepatitis

 

  • First line
  • Second line
  • Specialist
  • Hospital